The effect of probiotic and synbiotic supplementation on biomarkers of inflammation and oxidative stress in diabetic patients: A systematic review and meta-analysis of randomized controlled trials

Zheng, Hui Juan; Guo, Jing; Jia, Qi; Huang, Yi; Huang, Weijun; Zhang, Wenting; Zhang, Fan; Liu, Wei Jing; Wang, Yaoxian

doi:10.1016/j.phrs.2019.02.016

Cited by 91 publications

(48 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In T2DM patients, probiotics were found to lower the concentrations of hs-CRP, IL-6, and TNF-α [ 106 ]. Similar results, regarding hs-CRP, were demonstrated lately in a meta-analysis by Zheng et al [ 107 ] and by Tabrizi et al [ 108 ]. At last, the increase of the bioavailability of gliclazide regulating the intestinal absorption of glucose may also play a role [ 93 ].…”

Section: Discussionsupporting

confidence: 86%

The Effect of Probiotics and Synbiotics on Risk Factors Associated with Cardiometabolic Diseases in Healthy People—A Systematic Review and Meta-Analysis with Meta-Regression of Randomized Controlled Trials

Skonieczna-Żydecka

Kaźmierczak-Siedlecka

Kaczmarczyk

et al. 2020

JCM

View full text Add to dashboard Cite

We aimed to systematically review the effectiveness of probiotic/synbiotic formulations to counteract cardiometabolic risk (CMR) in healthy people not receiving adjunctive medication. The systematic search (PubMed/MEDLINE/Embase) until 1 August 2019 was performed for randomized controlled trials in >20 adult patients. Random-effect meta-analysis subgroup and meta-regression analysis of co-primary (haemoglobin A1c (HbA1C), glucose, insulin, body weight, waist circumference (WC), body mass index (BMI), cholesterol, low-density lipoproteins (LDL), high-density lipoproteins (HDL), triglycerides, and blood pressure) and secondary outcomes (uric acid, plasminogen activator inhibitor-1–PAI-1, fibrinogen, and any variable related to inflammation/endothelial dysfunction). We included 61 trials (5422 persons). The mean time of probiotic administration was 67.01 ± 38.72 days. Most of probiotic strains were of Lactobacillus and Bifidobacterium genera. The other strains were Streptococci, Enterococci, and Pediococci. The daily probiotic dose varied between 106 and 1010 colony-forming units (CFU)/gram. Probiotics/synbiotics counteracted CMR factors (endpoint data on BMI: standardized mean difference (SMD) = −0.156, p = 0.006 and difference in means (DM) = −0.45, p = 0.00 and on WC: SMD = −0.147, p = 0.05 and DM = −1.21, p = 0.02; change scores on WC: SMD = −0.166, p = 0.04 and DM = −1.35, p = 0.03) in healthy persons. Overweight/obese healthy people might additionally benefit from reducing total cholesterol concentration (change scores on WC in overweight/obese: SMD: −0.178, p = 0.049). Poor quality of probiotic-related trials make systematic reviews and meta-analyses difficult to conduct and draw definite conclusions. “Gold standard” methodology in probiotic studies awaits further development.

show abstract

Section: Discussionsupporting

confidence: 86%

The Effect of Probiotics and Synbiotics on Risk Factors Associated with Cardiometabolic Diseases in Healthy People—A Systematic Review and Meta-Analysis with Meta-Regression of Randomized Controlled Trials

Skonieczna-Żydecka

Kaźmierczak-Siedlecka

Kaczmarczyk

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Obviously, reliable biomarkers may not be available for all these types of interventions. Over the last year, however, the increased number of reports on microbiotarelated interventions has resulted in a large number of disease markers that have been impacted directly or indirectly by the respective interventions (Table 2) [41][42][43][44][45][46] . It is important to discriminate between general diseaserelated biomarkers and biomarkers for the microbiota.…”

Section: How Can the Efficacy Of Lbps Be Demonstrated?mentioning

confidence: 99%

Live biotherapeutic products: the importance of a defined regulatory framework

Rouanet²,

2020

View full text Add to dashboard Cite

Probiotics have been defined as “Live microorganisms that when administered in adequate amounts confer a health benefit on the host”. This definition covers a wide range of applications, target populations and (combinations of) microorganisms. Improved knowledge on the importance of the microbiota in terms of health and disease has further diversified the potential scope of a probiotic intervention, whether intended to reach the market as a food, a food supplement or a drug, depending on the intended use. However, the increased interest in the clinical application of probiotics may require specific attention given their administration in a diseased population. In addition to safety, the impact of the type of product, in terms of quality, production method and, e.g., the acceptance of side effects, is now part of the current regulatory constraints for developers. In the European Union, foods are regulated by the European Food Safety Authority and drugs by the European Medicines Agency; in the United States, the Food and Drug Administration (FDA) deals with both categories. More recently, the FDA has defined a new “live biotherapeutic products” (LBP) category, clarifying pharmaceutical expectations. Since 2019, the quality requirements for this category of drug products have also been clarified by the European Pharmacopoeia (Ph. Eur.). Similar to all products intended to prevent or treat diseases, LBPs will have to be registered as medicinal products to reach the market in the US and in Europe. In this area, regulatory authorities and the pharmaceutical industry will routinely use guidelines of the “International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use” (ICH). Although ICH guidelines are not legally binding, they provide very important recommendations, recognized by almost all drug authorities in the world. In this review, we discuss some aspects of this regulatory framework, especially focusing on products with an intended use in a diseased or vulnerable target population.

show abstract

“…There are only a handful of studies investigating the impact of synbiotics on cognition, and even fewer that utilize a polyphenolic prebiotic. In general, clinical studies with synbiotics are inconclusive as there are a broad cohort diversities and inadequate regulation of treatment regimens as was demonstrated with meta-analyses on IBS patients (Ford et al, 2018), ulcerative colitis (Asto et al, 2019), and diabetes (Zheng et al, 2019). Nevertheless, a few notable studies have been conducted to date demonstrating the potential of synbiotics to act as powerful therapeutic agents in the management of neurological disorders.…”

Section: The Gut Microbiota Increases Bioavailability Of Dietary Polymentioning

confidence: 99%

The Gut Microbiota Links Dietary Polyphenols With Management of Psychiatric Mood Disorders

Westfall

Pasinetti

2019

Front. Neurosci.

View full text Add to dashboard Cite

The pathophysiology of depression is multifactorial yet generally aggravated by stress and its associated physiological consequences. To effectively treat these diverse risk factors, a broad acting strategy is required and is has been suggested that gut-brain-axis signaling may play a pinnacle role in promoting resilience to several of these stress-induced changes including pathogenic load, inflammation, HPA-axis activation, oxidative stress and neurotransmitter imbalances. The gut microbiota also manages the bioaccessibility of phenolic metabolites from dietary polyphenols whose multiple beneficial properties have known therapeutic efficacy against depression. Although several potential therapeutic mechanisms of dietary polyphenols toward establishing cognitive resilience to neuropsychiatric disorders have been established, only a handful of studies have systematically identified how the interaction of the gut microbiota with dietary polyphenols can synergistically alleviate the biological signatures of depression. The current review investigates several of these potential mechanisms and how synbiotics, that combine probiotics with dietary polyphenols, may provide a novel therapeutic strategy for depression. In particular, synbiotics have the potential to alleviate neuroinflammation by modulating microglial and inflammasome activation, reduce oxidative stress and balance serotonin metabolism therefore simultaneously targeting several of the major pathological risk factors of depression. Overall, synbiotics may act as a novel therapeutic paradigm for neuropsychiatric disorders and further understanding the fundamental mechanisms of gut-brain-axis signaling will allow full utilization of the gut microbiota’s as a therapeutic tool.

show abstract

The effect of probiotic and synbiotic supplementation on biomarkers of inflammation and oxidative stress in diabetic patients: A systematic review and meta-analysis of randomized controlled trials

Cited by 91 publications

References 48 publications

The Effect of Probiotics and Synbiotics on Risk Factors Associated with Cardiometabolic Diseases in Healthy People—A Systematic Review and Meta-Analysis with Meta-Regression of Randomized Controlled Trials

The Effect of Probiotics and Synbiotics on Risk Factors Associated with Cardiometabolic Diseases in Healthy People—A Systematic Review and Meta-Analysis with Meta-Regression of Randomized Controlled Trials

Live biotherapeutic products: the importance of a defined regulatory framework

The Gut Microbiota Links Dietary Polyphenols With Management of Psychiatric Mood Disorders

Contact Info

Product

Resources

About